Mipomersen Sodium
Phase 3CompletedDevelopment Stage
Lipid Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Apr 1, 2008 → Sep 1, 2014
About Mipomersen Sodium
Mipomersen Sodium is a phase 3 stage product being developed by Ionis Pharmaceuticals for Lipid Metabolism, Inborn Errors. The current trial status is completed. This product is registered under clinical trial identifier NCT00694109. Target conditions include Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias.
What happened to similar drugs?
20 of 20 similar drugs in Lipid Metabolism, Inborn Errors were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00694109 | Phase 3 | Completed |
| NCT00477594 | Phase 2 | Completed |
Competing Products
20 competing products in Lipid Metabolism, Inborn Errors